Newron Pharmaceuticals’ add-on schizophrenia treatment improved both positive and negative symptoms as well as severity in ...

Harmony Biosciences is adding a suite of epilepsy assets to its pipeline, buying Epygenix for $35 million upfront with more ...

GSK and Genomics plc will collaborate on a new precision medicine initiative that assesses how genetic data can be used in ...

Novartis is pumping another $180 million into its radioligand plan, handing the cash to serial dealmaker PeptiDream to expand ...

Biometric CRO Quanticate will work with PhaseV, a machine learning company developing software for clinical trials, to launch ...

GE HealthCare missed its revenue goals for the first quarter after sales in China dipped 11%, compared to the boosts the company saw in the region during the same period the year prior. Overall, ...

Researchers have identified new enzymes that bring science closer to developing universal donor blood.  | Finally, some ...

Philips has reached a $1.1 billion agreement to settle claims from about 58,000 people stemming from its yearslong recall of ...

Abbott has returned to the field of bio-absorbable, dissolving stents, and in somewhat uncharted territory. | Abbott has ...

The U.S. FDA is planning to hold an advisory committee meeting on…well, advisory committee meetings. | The U.S. FDA is ...

Addex Therapeutics’ run of bad luck in the clinic shows no sign of ending, as a Janssen-licensed epilepsy drug has failed to ...

Annovis Bio heralded a “significantly higher rate of improvement” in patients with Alzheimer’s disease who received ...